Business
BioInvent to Present Phase 1 Clinical Data for BI-1910, a TNFR2 Agonist for the Treatment of Solid Tumors, at SITC
As previously reported, the single agent dose escalation of BI-1910 in the Phase 1 study was completed without any notable adverse events Updated clinical data will be presented at the Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual ...
About this update from Bioinvent International Ab
[{"type":"list","items":[{"val":[{"type":"text","content":"As previously reported, the single agent dose escalation of BI-1910 in the Phase 1 study was completed without any notable adverse events","length":137,"tagName":"p"}]},{"val":[{"type":"text","content":"Updated clinical data will be presented at the Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting to be held November 5-9, 2025, at National Harbor, MD (USA)","length":181,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":318,"olType":false},{"type":"text","content":"LUND, SE / ACCESS Newswire / October 3, 2025 / BioInvent International AB ("BioInvent") (STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, will present a poster with data from its trial of BI-1910 at the upcoming SITC Annual Meeting. The abstract title, which was released today, is "Preliminary Phase 1 results of clinical trial investigating BI-1910, a Tumor Necrosis Factor Receptor 2 (TNFR2) agonist in solid cancer tumor patients."","length":582,"tagName":"p"},{"type":"text","content":"BI-1910 is part of BioInvent's tumor-associated regulatory T cells (Treg)-targeting program, where currently the most advanced program, the Phase 2 program BI-1808, has been prioritized. As announced in August of this year, following a comprehensive strategic review - BioInvent decided to concentrate on advancing BI-1808 (as well as BI-1206, an FcyRIIB-blocking antibody). As part of this review, BioInvent is pausing the development of BI-1910.","length":451,"tagName":"p"},{"type":"text","content":"TNFR2 is particularly upregulated on Tregs of the tumor microenvironment and has been shown to be important for tumor expansion and survival, representing a new and promising target for cancer immunotherapy.","length":207,"tagName":"p"},{"type":"text","content":"Poster details:Title: Preliminary Phase 1 results of clinical trial investigating BI-1910, a Tumor Necrosis Factor Receptor 2 (TNFR2) agonist in solid cancer tumor patients.Abstract number: 581Date: November 7-8, 2025Authors: Hernandez T., Doger B., Yachnin J., Staahl Rorberg K., Moreno I., Carneiro A., Falcon Gonzalez A., Holmkvist P., Karlsson I., Lindahl D., Meller M., Mårtensson L., Schoenborn-Kellenberger O., Sunds...